TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16571285
Drug: SFI post-treatment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SFI post-treatment with GP regimen
Study: 14763252
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy and explanatory psychotherapy (Group 2, 18 patients)
Study: 10873968
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for three months
Study: 3942304
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg epidural morphine
Study: 3942304
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg epidural morphine
Study: 3942304
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg epidural morphine)
Study: 30022244
Drug: Outpatient spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient spa therapy
Study: 30022244
Drug: Inpatient spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient spa therapy
Study: 30022244
Drug: Etodolac treatment
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac treatment
Study: 26850424
Drug: Corticosteroid in
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid in periarticular injection
Study: 26850424
Drug: No corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corticosteroid in periarticular injection
Study: 24965739
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (n=126)
Study: 24965739
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment (n=117)
Study: 20347369
Drug: 150-mg monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-mg monthly oral ibandronate
Study: 18394048
Drug: levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levetiracetam (LEV) 3000 mg
Study: 1383816
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of finasteride per day
Study: 1383816
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of finasteride per day
Study: 30369135
Drug: 4HPR-L group
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4HPR-L group
Study: 26931192
Drug: Probiotics (bifidobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (bifidobacillus and lactobacillus) administered once daily by nasogastric tube from the third day of life
Study: 15326237
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for 42 days, followed by forced dose escalation to 10 mg/day)
Study: 9751447
Drug: Hydrocolloidal-based matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloidal-based matrix tablet (optimized formulation)
Study: 9751447
Drug: Existing once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing once-daily diltiazem HC1 product (Dilacor XR 240mg)
Study: 7917729
Drug: Propofol 8
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 8 mg kg‐1 h‐1 followed by 4 mg kg‐1 h‐1 and fentanyl 15 micrograms kg‐1 (group 1)
Study: 7917729
Drug: Midazolam 3‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3‐6 mg and fentanyl 60 micrograms kg‐1 (group 2)
Study: 3279089
Drug: 5-Methoxypsoralen (5-MOP)
Normalized name: 5 methoxypsoralen
DrugBank: Bergapten (DB12216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Methoxypsoralen (5-MOP) administered at a high oral dosage (doubled from standard dosage)
Study: 30847444
Drug: Oral betahistine
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral betahistine
Study: 16965415
Drug: Mupirocin plus
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin plus hydrocortisone butyrate ointment
Study: 16965415
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment plus hydrocortisone butyrate ointment
Study: 15373933
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's Wort (SJW) 900 mg day(‐1) for 14 days
Study: 9253329
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IGF‐I (80 micrograms/kg.day) and GH (0.3 IU/kg.day)
Study: 8323473
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with dipyridamole (75 mg three times a day) and aspirin (330 mg three times a day)
Study: 3103983
Drug: Combined blunt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined blunt spatula debridement and trifluridine therapy
Study: 26080652
Drug: Empagliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 2.5 mg
Study: 25985246
Drug: PDA-001 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA-001 (1 unit or 4 units, 2 infusions 1 week apart) in phase 2a study
Study: 11885184
Drug: Implant length
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant length
Study: 1540597
Drug: Diltiazem (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (30 mg three times daily increasing to 60 mg three times daily at 1 month)
Study: 1540597
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium blocker (Control)
Study: 4048359
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg/kg)
Study: 28641469
Drug: Counselling (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling (6 group sessions, twice per week for 3 weeks)
Study: 25162603
Drug: DETERx 40-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DETERx 40-mg capsules intact
Study: 20374034
Drug: Neoadjuvant aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant aromatase inhibitors (AI) for 3 months
Study: 16062074
Drug: Oxaliplatin 130
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m2 every 21 days
Study: 7997500
Drug: Newly designed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newly designed partial subperiosteal implants
Study: 7997500
Drug: Classical design
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical design partial subperiosteal implants
Study: 31200668
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy from a psychiatric nurse
Study: 29798368
Drug: Intratympanic injection
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic injection of budesonide (BUD) 0.5 mg/ml
Study: 29798368
Drug: Intratympanic injection
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic injection of dexamethasone (DEX) 5 mg/ml
Study: 29798368
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (NS) solution (1 ml)
Study: 21977965
Drug: saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 2.5 mg once daily
Study: 18326612
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg Zn as zinc sulfate
Study: 18326612
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg Zn as zinc sulfate
Study: 18326612
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Zn as zinc sulfate
Study: 18326612
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Zn + 0.5 mg Cu as copper sulfate
Study: 17726807
Drug: Yasmin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yasmin (3 mg Drospirenone and 30 microg ethinylestradiol)
Study: 10883875
Drug: SRP+Metro (subgingival
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP+Metro (subgingival scaling and root planing with metronidazole 25% dental gel)
Study: 8735863
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP), 800 micrograms daily
Study: 1426202
Drug: Bronchodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator therapy alone (salbutamol or ipratropium bromide)
Study: 30295170
Drug: Satisfaction with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satisfaction with daily activities
Study: 30295170
Drug: Participation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation in daily activities
Study: 26381427
Drug: aprepitant, extended-duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprepitant, extended-duration dexamethasone and low-dose olanzapine (high-risk patients)
Study: 26381427
Drug: extended-duration dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: extended-duration dexamethasone and low-dose olanzapine (high-risk patients)
Study: 25038148
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) infusion during dynamic handgrip exercise (15% maximal effort)
Study: 25038148
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) infusion
Study: 19588075
Drug: Bleaching treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching treatment with a plasma arc lamp (Remewhite, Remedent)
Study: 7503851
Drug: Ketorolac 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1.0 mg/kg
Study: 7025778
Drug: Probucol (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (N = 61, continued therapy in open trial)
Study: 21442459
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (once-yearly intravenous dose)
Study: 21442459
Drug: Alendronate (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (once-weekly oral dose)
Study: 14686964
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg candesartan cilexetil
Study: 11848327
Drug: Cyclosporine-A (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine-A (6 mg/kg body weight in divided doses for six months)
Study: 11848327
Drug: Stanozolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol (1 mg/kg body weight/day in divided doses)
Study: 9166392
Drug: HRT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (2 mg estradiol valerate and 1 mg cyproterone acetate)
Study: 3391874
Drug: Unprotected EA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unprotected EA tablets
Study: 3391874
Drug: Acid-protected tablets
Normalized name: ALLANTOIN 5 mg in 1 g TOPICAL CREAM [Shelo NABEL CACAO Skin Protectan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-protected tablets
Study: 3391874
Drug: Unprotected tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unprotected tablet
Study: 3391874
Drug: Protected tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protected tablet
Study: 3391874
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg acid-protected tablets
Study: 3391874
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acid-protected tablets
Study: 30599425
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone (14 mg tapered over 3 days)
Study: 30599425
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (target 80–110 mg·dL−1)
Study: 30599425
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose control (target 180–200 mg·dL−1)
Study: 25936640
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MPH
Study: 25936640
Drug: Continuous MPH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous MPH administration
Study: 23714959
Drug: Guiding elastic
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guiding elastic therapy (arch bar and elastics without rigid intermaxillary fixation for 7 to 12 days)
Study: 8576810
Drug: L-carnitine supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplemented lipid emulsion
Study: 999987
Drug: Naltrexone (40-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (40-200 mg per day)
Study: 30531488
Drug: Nitrate-rich (NR)
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich (NR) supplement
Study: 30531488
Drug: Nitrate-poor (NP)
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-poor (NP) supplement
Study: 23632723
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of quadrivalent HPV vaccine at 0 and 6 months (n = 259)
Study: 23632723
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261 for girls, n = 310 for young women)
Study: 21196672
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg ephedrine
Study: 21196672
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg ephedrine
Study: 21196672
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg ephedrine
Study: 21196672
Drug: 1.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 μg/kg phenylephrine
Study: 18059067
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET) group programme, 4 sessions in addition to routine hospital care
Study: 17156590
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about physical exercise after one cycle of cytotoxic drugs
Study: 17156590
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (information about physical exercise after two cycles of cytotoxic drugs)
Study: 10460951
Drug: Alpha-1-proteinase inhibitor
Normalized name: alpha-1-proteinase inhibitor
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-1-proteinase inhibitor (A1PI) supplementation at 60 mg/kg on days 0, 4, 7, and 14
Study: 8549573
Drug: Drink A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink A (2 mmol.l‐1 sodium)
Study: 8549573
Drug: Drink B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink B (26 mmol.l‐1 sodium)
Study: 8549573
Drug: Drink C
Normalized name: Boost Energy Drink Chocolate Raspberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink C (52 mmol.l‐1 sodium)
Study: 8549573
Drug: Drink D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink D (100 mmol.l‐1 sodium)
Study: 27449714
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (30 mg/kg) infused intravenously 15 minutes before tourniquet inflation
Study: 27449714
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (30 mg/kg) infused intravenously 15 minutes after tourniquet inflation
Study: 27449714
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (30 mg/kg) infused intravenously on tourniquet deflation
Study: 27449714
Drug: No tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No tranexamic acid administration
Study: 17365917
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg/day) + Amoxicillin (750 mg/day) + Clarithromycin (400 mg/day) for 7 days
Study: 17365917
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg/day) + Clarithromycin (400 mg/day) for 7 days
Study: 9862244
Drug: CGP 56697
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 4 x 4 tablets over 48 h
Study: 9862244
Drug: CGP 56697
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 4 x 2 tablets over 48 h
Study: 9862244
Drug: CGP 56697
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 3 x 4 tablets over 24 h
Study: 2618634
Drug: One-stage treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage treatment
Study: 24493296
Drug: Two-stage treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage treatment
Study: 35192
Drug: Clobazam 30
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam 30 mg
Study: 35192
Drug: Dipotassium clorazepate
Normalized name: Dipotassium clorazepate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipotassium clorazepate 15 mg
Study: 31900758
Drug: High CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CRP levels (> 3 mg/L)
Study: 31447131
Drug: Niacin-laropiprant (2000/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin-laropiprant (2000/40 mg/d)
Study: 26179616
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement with added micronutrients
Study: 26179616
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement without added micronutrients
Study: 23354657
Drug: Topical hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hemoglobin solution added to standard wound care
Study: 21859640
Drug: Mucosolvin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosolvin (15 mg/kg per day)
Study: 21859640
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no respiratory drug)
Study: 16437139
Drug: Sequential ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential ATRA and chemotherapy
Study: 16437139
Drug: Pre-therapy detection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-therapy detection
Study: 16437139
Drug: Subsequent ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subsequent ATRA therapy
Study: 12579384
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg i.v. preoperatively followed by 8 mg every 8 h for a total of 24 mg in the first 24 h
Study: 12579384
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg i.v. bolus before the end of the operation followed by 8 mg every 8 h for a total of 24 mg in the first 24 h
Study: 30941063
Drug: Quitlink intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quitlink intervention with peer worker support and referral to the Victorian Quitline for an 8-week cognitive behavioral intervention and nicotine replacement therapy (NRT)
Study: 21206285
Drug: High-dosage right
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage right unilateral (RUL) ECT
Study: 21206285
Drug: Moderate-dosage bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dosage bilateral (BL) ECT
Study: 21206285
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with VEN + Li
Study: 21206285
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with NT + Li
Study: 19273782
Drug: Bezafibrate therapy
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate therapy (n = 1509)
Study: 19273782
Drug: Bezafibrate therapy
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate therapy with upper-tertile HDL-C response (>8 mg/dL)
Study: 19273782
Drug: Bezafibrate therapy
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate therapy with lower-tertile HDL-C response (<=8 mg/dL)
Study: 19273782
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (n = 1517)
Study: 17970879
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate 300 mg q.i.d., lansoprazole 30 mg b.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d. (BLTM group) for 14 days
Study: 17970879
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. (LAC group) for 14 days
Study: 11730781
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with artemether and praziquantel
Study: 7909912
Drug: Propranolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.1 mg.kg‐1 body weight) administered intravenously after exercise